Description
Product Specifications
- Product: Semax 30mg
- Compound / formulation: Semax (synthetic ACTH-fragment-derived peptide)
- Labeled quantity / volume: 30mg per vial
- Physical form: White lyophilized powder
- Research focus: Neural Signaling Research; Stroke-Recovery Research; Neurotrophic Factor Research; Brain Network Research
- Available batch identifiers: Green cap
- SKU: HOP-SEMAX-30MG
- Intended classification: Laboratory research only
The labeled quantity is the catalog description and is not presented as an independently measured result for every vial.
Independent Laboratory Testing
Green cap — Janoshik Analytical, report #86676
- Compound reported: Semax 30mg
- Measured content: 31.20mg
- Purity: 99.634%
- Test date: November 7, 2025
- View laboratory report
House of Peptides maintains an established testing and sampling protocol with its suppliers. Under this agreed protocol, samples are randomly selected from a production batch and submitted for independent laboratory analysis.
The submitted samples are drawn from the same production batch as the corresponding inventory supplied to House of Peptides. This batch-based sampling approach provides analytical information associated with the production batch rather than individual testing of every vial.
House of Peptides may maintain inventory from multiple production batches of the same compound. Each Certificate of Analysis corresponds to its identified batch, which may be distinguished by cap color or lot designation. Orders are fulfilled on a first-in, first-out (FIFO) basis, so the batch supplied depends on available inventory at the time of fulfillment. Laboratory findings apply to the submitted samples from their respective batches, not to every individual vial.
Scientific Research Background
The brain relies on billions of nerve cells sending signals to one another. Scientists study how those signals change during everyday activity and after an injury, such as a stroke, when blood flow to part of the brain is interrupted.
Semax is a synthetic peptide consisting of seven amino acids. Its first four amino acids come from a segment of a naturally occurring hormone called ACTH, followed by three additional amino acids. The modified peptide is studied as its own compound; its structure does not mean it has the same effects as the full hormone.
One area of research concerns proteins that support the growth and communication of nerve cells. One such protein is called BDNF, often described as a factor involved in how nerve cells adapt and maintain connections. Researchers have measured changes in BDNF-related signals in animals exposed to Semax, but those findings cannot be assumed to occur in the human brain.
Human studies have explored Semax in people recovering from stroke and in small groups of healthy volunteers undergoing brain imaging. Those studies examined specific measurements under controlled conditions. They do not demonstrate improved everyday concentration or memory in healthy people, and they do not establish clinical benefits for commercially sourced research vials.
Compound details
- Amino-acid sequence: Met–Glu–His–Phe–Pro–Gly–Pro (MEHFPGP)
- Peptide length: Seven amino acids
- Research classification: Neural signaling and neurotrophic-factor research
Clinical Research Observations
1. Why do researchers study Semax and the brain?
The brain is constantly adjusting how its cells communicate. Scientists investigate these changes to understand learning, responses to injury, and how different parts of the brain work together.
What researchers found: Semax has been studied in animal experiments, small human studies, and laboratory research. The work has focused on brain-cell signaling and changes observed after interrupted blood flow to the brain.
Why it matters: These studies identify questions worth investigating. They do not establish that Semax improves thinking, memory, or brain health in the general population.
2. What did scientists see when they scanned the brains of healthy volunteers?
A brain scan can show patterns of activity across connected regions, even while a person is resting. Those patterns are not the same as a test of attention or memory.
What researchers found: In a 2018 study involving 24 healthy volunteers, 14 received a Semax preparation and 10 received a placebo. Scans were taken before exposure and again 5 and 20 minutes afterward. Researchers reported changes in a frontal part of the brain’s resting-state network. The accessible report describes a change between the two later scans in the Semax group; the placebo group also showed changes over time.
Why it matters: A change in a brain scan is not the same as better concentration or memory. Such signals can also reflect changes in blood flow, and this small experiment did not demonstrate improved everyday performance.
3. What happened when Semax was studied during stroke recovery?
A stroke can affect movement and independence. Researchers often measure recovery by asking how well a person can manage daily activities and how their movement changes over time.
What researchers found: A 2018 study followed 110 people undergoing rehabilitation after an ischemic stroke. Researchers divided participants into earlier and later rehabilitation groups, then compared subgroups receiving Semax with those not receiving it. They reported higher blood BDNF levels and improvements in measures of daily functioning, especially the Barthel Index, among Semax recipients.
Why it matters: The findings are specific to people recovering from stroke while receiving rehabilitation. The study measured recovery in people who had experienced a stroke, not cognition in healthy people. Its subgroup comparisons do not isolate every possible influence of rehabilitation timing or establish broad clinical effectiveness.
4. What did an earlier stroke study report?
Researchers sometimes compare people receiving an experimental treatment with others receiving conventional care. How those groups are selected matters because differences between them can affect the results.
What researchers found: A 1997 report described 30 stroke patients who received Semax as part of treatment and a comparison group of 80 patients receiving conventional care. The investigators reported faster improvement on some neurological measures in the Semax group.
Why it matters: The comparison groups were unequal in size, and the accessible abstract does not establish a blinded, randomized design. These findings cannot be treated as definitive proof of a treatment benefit.
5. Why do scientists study a protein called BDNF?
BDNF helps researchers understand how nerve cells maintain and adapt their connections. Measuring it can provide clues about a biological response, but a change in BDNF is not itself proof of better memory or recovery.
What researchers found: In a 2006 rat study, investigators reported increased BDNF protein in one part of the brain after Semax exposure. They did not observe the same increase in every brain region examined.
Why it matters: The findings suggest that the response may depend on which part of the brain is studied. Results in rat brain tissue do not establish an equivalent effect in humans.
6. Did laboratory experiments show the same response everywhere in the brain?
Different brain regions have different roles, and their cells may respond differently to the same experimental substance.
What researchers found: A 2007 rat study measured gene activity after Semax exposure. activity of genes related to BDNF and NGF increased in the hippocampus; BDNF-related expression also increased in the brainstem and cerebellum, while NGF-related expression decreased in the frontal cortex.
Why it matters: The response depended on both the gene and the brain region. These were measurements of gene activity in rats, not proof of higher protein levels everywhere in the brain or better mental performance in humans.
7. What can we conclude about Semax and mental performance?
Interest in a compound does not establish a benefit. Researchers need well-designed studies that measure outcomes people can actually experience, not just changes on a scan or in a laboratory sample.
What researchers found: Published work includes small human brain-imaging and stroke studies, along with animal research on cell signaling. The studies have important limitations, and these findings do not establish improved focus, memory, or learning in healthy people.
Why it matters: Semax remains a subject for further investigation. These publications do not establish that House of Peptides' Semax 30mg has therapeutic benefits or is safe for human administration.
Published Scientific Research
The following studies used research or clinical preparations of Semax. They do not establish the clinical properties of House of Peptides' Semax 30mg.
Lebedeva et al. (2018) — Effects of Semax on the Default Mode Network of the Brain. Bulletin of Experimental Biology and Medicine. Brain-imaging study involving 24 healthy volunteers. PubMed — PMID 30225715. DOI:
10.1007/s10517-018-4234-3. Supports: Question 2.Gusev et al. (2018) — Semax during post-stroke rehabilitation. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova. Study of 110 people undergoing post-stroke rehabilitation. PubMed — PMID 29798983. DOI:
10.17116/jnevro20181183261-68. Supports: Question 3.Gusev et al. (1997) — Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova. Report comparing 30 patients receiving Semax with 80 conventional-care controls. PubMed — PMID 11517472. Supports: Question 4.
Dolotov et al. (2006) — Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry. Animal study of BDNF protein and binding observations. PubMed — PMID 16635254. DOI:
10.1111/j.1471-4159.2006.03658.x. Supports: Question 5.Agapova et al. (2007) — Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neuroscience Letters. Rat study of region-specific changes in nerve-growth-related gene signals. PubMed — PMID 17353092. DOI:
10.1016/j.neulet.2007.02.042. Supports: Question 6.
Evidence boundary: These studies differ in their populations, methods, and measurements. Human stroke-rehabilitation findings cannot be extrapolated to healthy people, and animal or brain-imaging findings do not establish a cognitive benefit or safety profile for this research inventory.
Understanding the Research Findings
Semax is a seven-amino-acid peptide investigated in studies of brain-cell signaling and neurological recovery.
Researchers have reported changes in brain-imaging measurements among healthy volunteers, selected rehabilitation outcomes in people recovering from stroke, and nerve-cell-related proteins in animal experiments. The findings vary by study design and cannot be combined into a single claim that Semax improves memory, focus, or brain health.
Published studies do not establish equivalent clinical effects or safety for House of Peptides’ independently sourced Semax 30mg. The laboratory measurements apply to the identified sample and do not establish clinical effectiveness.
Research Use Notice
For laboratory research only. Not intended for human or veterinary administration, diagnostic, or therapeutic use.
Reviews
There are no reviews yet.